KR102622245B1 - 근육 성능 개선 화합물 - Google Patents

근육 성능 개선 화합물 Download PDF

Info

Publication number
KR102622245B1
KR102622245B1 KR1020197018624A KR20197018624A KR102622245B1 KR 102622245 B1 KR102622245 B1 KR 102622245B1 KR 1020197018624 A KR1020197018624 A KR 1020197018624A KR 20197018624 A KR20197018624 A KR 20197018624A KR 102622245 B1 KR102622245 B1 KR 102622245B1
Authority
KR
South Korea
Prior art keywords
leu
val
ser
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197018624A
Other languages
English (en)
Korean (ko)
Other versions
KR20190085132A (ko
Inventor
얀 빌렘 브리플뢰트
마리나 마리아 보이도
올레나 부텐코
로베르타 셸리노
Original Assignee
파르마폭스 테라퓨틱스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마폭스 테라퓨틱스 아게 filed Critical 파르마폭스 테라퓨틱스 아게
Publication of KR20190085132A publication Critical patent/KR20190085132A/ko
Application granted granted Critical
Publication of KR102622245B1 publication Critical patent/KR102622245B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197018624A 2016-11-29 2017-11-28 근육 성능 개선 화합물 Active KR102622245B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds
GB1620119.6 2016-11-29
PCT/IB2017/057436 WO2018100483A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Publications (2)

Publication Number Publication Date
KR20190085132A KR20190085132A (ko) 2019-07-17
KR102622245B1 true KR102622245B1 (ko) 2024-01-05

Family

ID=58073474

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018624A Active KR102622245B1 (ko) 2016-11-29 2017-11-28 근육 성능 개선 화합물

Country Status (11)

Country Link
US (1) US11407799B2 (enExample)
EP (1) EP3548509A1 (enExample)
JP (2) JP7683901B2 (enExample)
KR (1) KR102622245B1 (enExample)
CN (1) CN110036024B (enExample)
AU (1) AU2017367277B2 (enExample)
CA (1) CA3045245A1 (enExample)
GB (1) GB201620119D0 (enExample)
NZ (1) NZ754625A (enExample)
WO (1) WO2018100483A1 (enExample)
ZA (1) ZA201903261B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7051846B2 (ja) 2016-11-10 2022-04-11 ケロス セラピューティクス インコーポレイテッド アクチビンIIa型受容体変異体および同変異体を含む医薬組成物
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンIIa型受容体変異体を含む医薬組成物
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
CA3098679A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND THEIR USES
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US20230257435A1 (en) * 2020-07-24 2023-08-17 Agency For Science, Technology And Research Wound Healing Composition and Uses Thereof
CA3211515A1 (en) * 2021-03-10 2022-09-15 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
BR112023018283A2 (pt) * 2021-03-10 2023-10-31 Acceleron Pharma Inc Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca
IL309562A (en) 2021-06-21 2024-02-01 Juvena Therapeutics Inc Regenerative polypeptides and their uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516886A (ja) 2002-10-25 2006-07-13 ワイエス Actriib融合ポリペプチドおよびその使用
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
JP2010502633A (ja) 2006-09-05 2010-01-28 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
US20110135638A1 (en) 2009-11-17 2011-06-09 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2012525128A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
JP2013503825A (ja) * 2009-09-04 2013-02-04 ニューロチューン・アクチエンゲゼルシャフト 薬物として用いる、筋力を回復する能力がある改変アグリン断片

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2174098C (en) * 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP2056850A4 (en) 2006-08-08 2011-10-12 Univ Louisiana State THERAPEUTIC PROCEDURES FOR NEUROPATHIC PAIN
KR20160129095A (ko) 2007-02-09 2016-11-08 악셀레론 파마 인코포레이티드 액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516886A (ja) 2002-10-25 2006-07-13 ワイエス Actriib融合ポリペプチドおよびその使用
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
JP2010502633A (ja) 2006-09-05 2010-01-28 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
JP2012525128A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
JP2013503825A (ja) * 2009-09-04 2013-02-04 ニューロチューン・アクチエンゲゼルシャフト 薬物として用いる、筋力を回復する能力がある改変アグリン断片
US20110135638A1 (en) 2009-11-17 2011-06-09 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2013511474A (ja) * 2009-11-17 2013-04-04 アクセルロン ファーマ, インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するactriibタンパク質およびその改変体およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Experimental Gerontology 85(8962):1-8(2016.09.12.)
Nature Reviews Drug Discovery 14(1):58-74(2014.12.31.)

Also Published As

Publication number Publication date
KR20190085132A (ko) 2019-07-17
CA3045245A1 (en) 2018-06-07
EP3548509A1 (en) 2019-10-09
WO2018100483A1 (en) 2018-06-07
AU2017367277A1 (en) 2019-07-04
JP7683901B2 (ja) 2025-05-27
CN110036024A (zh) 2019-07-19
ZA201903261B (en) 2020-02-26
GB201620119D0 (en) 2017-01-11
AU2017367277B2 (en) 2021-04-01
US20210253654A1 (en) 2021-08-19
JP2019536818A (ja) 2019-12-19
US11407799B2 (en) 2022-08-09
JP2023116479A (ja) 2023-08-22
CN110036024B (zh) 2024-05-07
NZ754625A (en) 2023-03-31

Similar Documents

Publication Publication Date Title
KR102622245B1 (ko) 근육 성능 개선 화합물
JP7427046B2 (ja) Bdnfを含む融合蛋白質
JP4790624B2 (ja) 生体分子パーティションモチーフ及びそれらの使用
JP4222629B2 (ja) ニュールツリンおよび関連成長因子
JP2021527656A (ja) プログラニュリンを含む融合タンパク質
CA3049023A1 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
SK4512002A3 (en) April-r antagonist for the treatment of diseases related to undesirable cell proliferation
US12384822B2 (en) TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity
JP2020524661A (ja) 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp−1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
JP2014502965A (ja) uPARアンタゴニストおよびその使用
JP2017513921A (ja) ジストロフィン異常症を治療するためのキメラジストロフィン−vsv−gタンパク質
AU2002332732A1 (en) Bv8 nucleic acids and polypeptides with mitogenic activity
WO2003020892A2 (en) Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
ES2259458T3 (es) Persefina humana.
CN101627053A (zh) 泛细胞表面受体特异的治疗剂
WO2016143702A1 (ja) 抗ヒト膜型adam28抗体
RU2846293C1 (ru) АНТИТЕЛО К EphA4
AU2016211890B2 (en) Methods and Compositions for Regulating Iron Homeostasis by Modulation of BMP-6
US20240317867A1 (en) Igfr-like 2 receptor and uses thereof
KR20180120738A (ko) 톨-유사 수용체 4에 대한 길항제로서의 뉴몰리신 펩타이드의 용도 및 톨-유사 수용체 4 관련 질병을 치료하는 방법
KR20230123923A (ko) 항-EphA4 항체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201127

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230228

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231207

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240103

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240103

End annual number: 3

Start annual number: 1

PG1601 Publication of registration